Clinical efficacy and safety: antineoplastic and immunomodulating agents

The European Medicines Agency's scientific guidelines on the clinical evaluation of antineoplastic and immunomodulating agents help medicine developers prepare marketing authorisation applications.

For a complete list of scientific guidelines currently open for consultation, see Public consultations.

Guidelines

Reflection papers

Topics

How useful was this page?

Add your rating
Average
1 rating
3 ratings
1 rating
1 rating